Warberg Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Warberg Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6,000	Closed	-$16K	–	309
2022 Q2	$16K	Buy	6,000 +4,200	+233%	+$11.6K	﹤0.01%	190
2022 Q1	$6K	Buy	+1,800	New	+$9.32K	﹤0.01%	221
2021 Q4	–	Sell	-2,000	Closed	-$28K	–	224
2021 Q3	$28K	Hold	2,000	–	–	﹤0.01%	174
2021 Q2	$34K	Hold	2,000	–	–	0.01%	180
2021 Q1	$38K	Buy	+2,000	New	+$64.5K	0.01%	137

Other funds holding SLNO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Warberg Asset Management's SLNO Position: Q3 2022 in Review

Warberg Asset Management sold out of Soleno Therapeutics (SLNO) in Q3 2022, closing a stake of 6,000 shares — an estimated $16K sold.

Warberg Asset Management first reported a position in SLNO in Q1 2021 and held it in 5 quarters. The position peaked at $38K in Q1 2021. 22 funds tracked by Wall St. Rank hold SLNO as of Q3 2022.

Warberg Asset Management reported no remaining Soleno Therapeutics position as of Q3 2022 after selling out during the quarter.
Warberg Asset Management sold 6,000 Soleno Therapeutics shares in Q3 2022, an estimated $16K.
Warberg Asset Management first reported a position in Soleno Therapeutics in Q1 2021 and held it in 5 quarters.
Warberg Asset Management's Soleno Therapeutics position peaked at $38K in Q1 2021.
22 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2022.

Based on Warberg Asset Management's 13F filing for Q3 2022, filed 7 Nov 2022.